OBJECTIVE: To explore the relationship between metabolic activity and outcome in patients with extremity sarcomas. METHODS: Between June 2004 and December 2011, 120 patients with newly diagnosed limb and girdle sarcomas underwent FDG-PET/CT for disease staging prior to curative intent treatment. The maximum standardized uptake value (SUV(max)) was measured for each primary tumor and correlated with outcome. Progression-free survival and overall survival (OS) were analyzed using the Kaplan-Meier method. RESULTS: Soft-tissue sarcomas were more frequent (68%) than bone (27%) or cartilage (5%) tumors. Median follow-up was 33.2 months. 51% of patients progressed during the follow-up interval and 38% died. SUV(max) was dichotomized with a cut-point of 10.3. Patients with SUV(max) < 10.3 had better DFS and OS compared with patients with SUV(max) ≥ 10.3 (P < 0.001 and P < 0.001, respectively [log-rank test]). Multivariate analysis confirmed that even after adjusting for age, sex, site, tumor type (bone vs. soft-tissue), grade, and stage; an SUV(max) ≥ 10.3 correlated with a twofold risk of progression and 2.4 times greater risk of death (hazard ratio [HR] 2.0, 95% CI, 1.1-3.7, and HR, 2.4, 95% CI, 1.1-4.9). CONCLUSION: SUV(max) is an independent adverse prognostic factor for both progression and OS in patients with extremity sarcomas.
OBJECTIVE: To explore the relationship between metabolic activity and outcome in patients with extremity sarcomas. METHODS: Between June 2004 and December 2011, 120 patients with newly diagnosed limb and girdle sarcomas underwent FDG-PET/CT for disease staging prior to curative intent treatment. The maximum standardized uptake value (SUV(max)) was measured for each primary tumor and correlated with outcome. Progression-free survival and overall survival (OS) were analyzed using the Kaplan-Meier method. RESULTS: Soft-tissue sarcomas were more frequent (68%) than bone (27%) or cartilage (5%) tumors. Median follow-up was 33.2 months. 51% of patients progressed during the follow-up interval and 38% died. SUV(max) was dichotomized with a cut-point of 10.3. Patients with SUV(max) < 10.3 had better DFS and OS compared with patients with SUV(max) ≥ 10.3 (P < 0.001 and P < 0.001, respectively [log-rank test]). Multivariate analysis confirmed that even after adjusting for age, sex, site, tumor type (bone vs. soft-tissue), grade, and stage; an SUV(max) ≥ 10.3 correlated with a twofold risk of progression and 2.4 times greater risk of death (hazard ratio [HR] 2.0, 95% CI, 1.1-3.7, and HR, 2.4, 95% CI, 1.1-4.9). CONCLUSION: SUV(max) is an independent adverse prognostic factor for both progression and OS in patients with extremity sarcomas.
Authors: Kim Francis Andersen; Hanna Maria Fuglo; Sine Hvid Rasmussen; Michael Mork Petersen; Annika Loft Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889
Authors: Ruth E Macpherson; Sarah Pratap; Helen Tyrrell; Mehrdad Khonsari; Shaun Wilson; Max Gibbons; Duncan Whitwell; Henk Giele; Paul Critchley; Lucy Cogswell; Sally Trent; Nick Athanasou; Kevin M Bradley; A Bassim Hassan Journal: Clin Sarcoma Res Date: 2018-04-09
Authors: Matthew B Spraker; Landon S Wootton; Daniel S Hippe; Kevin C Ball; Jan C Peeken; Meghan W Macomber; Tobias R Chapman; Michael N Hoff; Edward Y Kim; Seth M Pollack; Stephanie E Combs; Matthew J Nyflot Journal: Adv Radiat Oncol Date: 2019-02-23
Authors: Douglas J Harrison; Yueh-Yun Chi; Jing Tian; Pooja Hingorani; Leo Mascarenhas; Geoffrey B McCowage; Brenda J Weigel; Rajkumar Venkatramani; Suzanne L Wolden; Torunn I Yock; David A Rodeberg; Andrea A Hayes-Jordan; Lisa A Teot; Sheri L Spunt; William H Meyer; Douglas S Hawkins; Barry L Shulkin; Marguerite T Parisi Journal: Cancer Med Date: 2020-12-19 Impact factor: 4.452
Authors: Martin Vallières; Monica Serban; Ibtissam Benzyane; Zaki Ahmed; Shu Xing; Issam El Naqa; Ives R Levesque; Jan Seuntjens; Carolyn R Freeman Journal: Phys Imaging Radiat Oncol Date: 2018-05-19
Authors: Kim Francis Andersen; Hanna Maria Fuglo; Sine Hvid Rasmussen; Michael Mork Petersen; Annika Loft Journal: Medicine (Baltimore) Date: 2015-12 Impact factor: 1.817